Zimmer Biomet (NYSE:ZBH) Stock Gets Price Target Increase from JPMorgan Chase & Co.

Key Points

• JPMorgan raised its Zimmer Biomet price target from $117 to $120 while keeping a neutral rating; the new target implies 12.07% upside from the prior close.
• Shares fell 2.8% to $107.08 during Thursday trading. Analysts overall have a consensus “Hold” rating and an average price target of $111.42.
• Zimmer Biomet reported quarterly adjusted EPS of $1.90, beating estimates of $1.88, and revenue of $2.06 billion, up 3.1% year over year.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from $117.00 to $120.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a "neutral" rating on the medical equipment provider's stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 12.07% from the stock's previous close.

A number of other research firms have also recently commented on ZBH. UBS Group reaffirmed a "buy" rating and set a $120.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Jefferies Financial Group reissued a "hold" rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research report on Wednesday. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a research note on Thursday, August 6th. Zacks Research raised Zimmer Biomet from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 25th. Finally, Wells Fargo & Company boosted their price target on Zimmer Biomet from $103.00 to $113.00 and gave the company an "equal weight" rating in a research note on Thursday. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $111.42.

Zimmer Biomet Stock Down 2.8%

Shares of NYSE ZBH traded down $3.07 during mid-day trading on Thursday, hitting $107.08. The company had a trading volume of 3,623,755 shares, compared to its average volume of 2,266,789. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The firm has a 50-day simple moving average of $94.90 and a two-hundred day simple moving average of $91.89. The company has a market capitalization of $20.42 billion, a PE ratio of 26.05, a price-to-earnings-growth ratio of 2.33 and a beta of 0.50. Zimmer Biomet has a one year low of $79.12 and a one year high of $112.54.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. During the same quarter in the prior year, the company posted $1.90 earnings per share. Zimmer Biomet's revenue was up 3.1% on a year-over-year basis. On average, equities analysts expect that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Activity at Zimmer Biomet

In related news, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider directly owned 65,231 shares of the company's stock, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. Company insiders own 1.28% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ZBH. Illinois Municipal Retirement Fund lifted its holdings in Zimmer Biomet by 5.4% during the third quarter. Illinois Municipal Retirement Fund now owns 111,122 shares of the medical equipment provider's stock valued at $9,871,000 after purchasing an additional 5,727 shares during the last quarter. Mesirow Financial Investment Management Inc. bought a new position in Zimmer Biomet during the third quarter worth about $209,000. Equity Investment Corp increased its stake in shares of Zimmer Biomet by 5.7% in the third quarter. Equity Investment Corp now owns 1,776,758 shares of the medical equipment provider's stock worth $157,829,000 after purchasing an additional 95,398 shares in the last quarter. M&G PLC increased its stake in shares of Zimmer Biomet by 0.3% in the third quarter. M&G PLC now owns 158,365 shares of the medical equipment provider's stock worth $14,094,000 after purchasing an additional 402 shares in the last quarter. Finally, AlphaCore Capital LLC increased its stake in shares of Zimmer Biomet by 25.2% in the third quarter. AlphaCore Capital LLC now owns 21,970 shares of the medical equipment provider's stock worth $1,952,000 after purchasing an additional 4,419 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, while adjusted EPS of $1.90 topped estimates of $1.88. The company also raised its full-year 2026 outlook; stronger hips and S.E.T. sales helped offset knee-market weakness. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its target to $125 and upgraded ZBH to “outperform,” providing a bullish signal. Royal Bank of Canada recommendations
• Neutral Sentiment: Citigroup lifted its target to $117 but kept a “neutral” rating. Wells Fargo raised its target to $113 and maintained “equal weight.” Citigroup recommendations Wells Fargo recommendations
• Negative Sentiment: Reported diluted EPS fell 13.8% to $1.00, while adjusted EPS was flat year over year. Knee weakness and margin pressure remain concerns; Bernstein raised its target to $107 but kept a “market perform” rating. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.